Event

31

October 2017

The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future

11:30am-1:30pm | Fairmont Chateau Laurier - 1 Rideau Street, Ottawa

What is the true contribution of the innovative pharmaceutical industry to the Canadian economy and R&D investment? What are the potential impacts of federal policy changes aimed at lowering drug prices? Is there a middle ground where Canada is able to lower prices while still retaining its position as a top tier destination for clinical trials and the launch of new innovative medicines? IMC President Pamela Fralick and panelists will discuss the results of a Fall 2017 analysis by EY about industry’s contributions to Canada and how industry and government can work together to enhance affordable, equitable and timely access to new therapies.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

Important:
- For information about accessibility, please email lapointe@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to dickinson@economicclub.ca by Thursday, October 26, 2017

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future

Connie Côté

CEO
Health Charities Coalition of Canada

Connie Côté

Connie Côté has been involved in the not-for-profit, regulatory and charitable health sector for over twenty years and is currently the Chief Executive Officer of the Health Charities Coalition of Canada (HCCC). Her priorities at HCCC include advocating on issues related to health research and health policy and working with members to identify areas of alignment and opportunity.

Prior to joining HCCC, Connie worked with the Canadian Lung Association where she held various management positions, including leading the National Lung Health Framework. Previously, she worked for the Federation of Medical Regulatory Authorities of Canada and the Royal College of Physicians and Surgeons of Canada.

Connie enjoys working within multi-disciplinary teams, navigating change and building strong partnerships.

Connie lives in Ottawa with her two children.

Dr. Bill Cameron

Senior Scientist, Division of Infectious Diseases and Respirology
Medical Director, Clinical Research, Ottawa Hospital Research Institute

Dr. Bill Cameron

Dr. Bill Cameron is Medical Director for Clinical Research at the Ottawa Hospital Research Institute, Senior Scientist for the Clinical Epidemiology Program at the Ottawa Hospital Research Institute, Professor for the Faculty of Medicine at The University of Ottawa, and physician for the Division of Infectious Diseases at The Ottawa Hospital. He has practiced general infectious disease medicine at The Ottawa Hospital for the last 29 years. In the past twenty years or more, Dr. Cameron’s work has made substantial impact in HIV epidemiology and therapeutics.

http://www.ohri.ca/profile/bcameron

Ed Dybka

President and CEO
AstraZeneca Canada Inc.

Ed Dybka

Ed Dybka is the President of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.

Mr. Dybka has worked in the Canadian pharmaceutical industry for close to 30 years and has led AstraZeneca Canada Inc since 2015. In 2012, he led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases and affiliated with Almirall S.A., with headquarters in Barcelona, Spain.

Prior to establishing Almirall in Canada, Mr. Dybka held a number of executive roles at GlaxoSmithKline Canada from 2004 to 2012, including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement. Earlier in his career, Mr. Dybka held progressively senior roles in product management and product development, as well as sales, at Glaxo Wellcome Canada Inc. and Zeneca Pharma Inc.

Mr. Dybka is currently a Co-Chair of Life Sciences Ontario, an organization that represents and promotes the province's vibrant and diverse life sciences sector. He is also the Chair of the Acute Coronary Treatment (ACT) Foundation and is a Director of Innovative Medicines Canada. He has served on a number of other Boards, including the George Hull Centre for Children and Families, the Pharmaceutical Advertising and Advisory Board, the Canadian Pharmaceutical Distribution Network, and The Mississauga Board of Trade.

Mr. Dybka holds a Bachelor of Science degree in Toxicology from the University of Toronto. He lives in Toronto with his wife and two children.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.

Pamela Fralick

President
Innovative Medicines Canada

Pamela Fralick

Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them.

Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a three-year process of intense transformation, resulting in historic changes to the operational and governance structures of the organization.

Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA) and as CEO of the Canadian Physiotherapy Association. At both Associations, Ms. Fralick led organizational initiatives designed to enhance sustainability and improve outcomes for the associations, their members and stakeholders. Ms. Fralick has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit.

True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the board of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair).

Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.

Our Sponsors